补体抑制治疗心肌梗死？
Complement inhibition to treat myocardial infarction?
作者信息
Gerber Bernhard, Kyburz Tatiana, Reinhart Walter H, Bonetti Piero O, Stussi Georg
机构信息
Department of Internal Medicine, Clinic of Haematology, University Hospital Zurich, Zurich, Switzerland.
出版信息
BMJ Case Rep. 2011 Apr 26;2011:bcr0120113701. doi: 10.1136/bcr.01.2011.3701.
Abstract
The authors describe the case of a middle-aged women who presented with an acute myocardial infarction due to thrombotic occlusion of angiographically normal coronary arteries. Coronary thrombosis was caused by a hypercoagulable state related to a haemolytic crisis of paroxysmal nocturnal haemoglobinuria and the patient was treated conservatively with antithrombotic agents. The clinical course was complicated by both severe bleeding and thrombotic complications and the patient eventually died of a massive intracerebral haemorrhage. The rapid occurrence of complications inhibited a timely administration of a specific treatment for complement-mediated haemolysis (eculizumab).
摘要
作者描述了一名中年女性的病例，该患者因血管造影正常的冠状动脉血栓闭塞而出现急性心肌梗死。冠状动脉血栓形成是由与阵发性夜间血红蛋白尿溶血危机相关的高凝状态引起的，患者接受了抗血栓药物的保守治疗。临床过程因严重出血和血栓并发症而复杂化，患者最终死于大面积脑出血。并发症的迅速出现阻碍了及时给予针对补体介导的溶血的特异性治疗（依库珠单抗）。
相似文献
1
Complement inhibition to treat myocardial infarction?补体抑制治疗心肌梗死？
BMJ Case Rep. 2011 Apr 26;2011:bcr0120113701. doi: 10.1136/bcr.01.2011.3701.
2
Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial.依库珠单抗联合口服因子 B 抑制剂依帕司他治疗阵发性睡眠性血红蛋白尿症伴溶血性贫血患者的开放标签、单臂、2 期概念验证试验
Lancet Haematol. 2021 May;8(5):e344-e354. doi: 10.1016/S2352-3026(21)00028-4. Epub 2021 Mar 23.
3
COVID-19 Presented with Deep Vein Thrombosis in a Patient with Paroxysmal Nocturnal Haemoglobinuria.COVID-19 合并阵发性睡眠性血红蛋白尿症患者发生深静脉血栓。
Hamostaseologie. 2021 Oct;41(5):397-399. doi: 10.1055/a-1554-6432. Epub 2021 Sep 20.
4
Hemolytic crisis in a patient treated with eculizumab for paroxysmal nocturnal hemoglobinuria possibly triggered by SARS-CoV-2 (COVID-19): a case report.1例接受依库珠单抗治疗的阵发性睡眠性血红蛋白尿患者发生溶血性危机，可能由SARS-CoV-2（新冠病毒病）触发：病例报告
Ann Hematol. 2021 Mar;100(3):841-842. doi: 10.1007/s00277-020-04318-6. Epub 2020 Nov 10.
5
Eculizumab therapy in paroxysmal nocturnal haemoglobinuria patient undergoing aortic valve surgery.接受主动脉瓣手术的阵发性夜间血红蛋白尿患者的依库珠单抗治疗。
Interact Cardiovasc Thorac Surg. 2019 Jun 1;28(6):994-995. doi: 10.1093/icvts/ivz020.
6
A cascade of thromboembolic processes in a patient with paroxysmal nocturnal haemoglobinuria terminated by treatment with eculizumab.一名阵发性夜间血红蛋白尿患者发生一系列血栓栓塞过程，经依库珠单抗治疗后终止。
Thromb Haemost. 2011 Aug;106(2):383-5. doi: 10.1160/TH11-03-0165. Epub 2011 Jun 9.
7
Successful treatment of a PNH patient non-responsive to eculizumab with the novel complement C5 inhibitor coversin (nomacopan).用新型补体C5抑制剂覆盖素（诺马科潘）成功治疗对依库珠单抗无反应的阵发性睡眠性血红蛋白尿症患者。
Br J Haematol. 2020 Jan;188(2):334-337. doi: 10.1111/bjh.16305. Epub 2019 Dec 16.
8
An unusual presentation of paroxysmal nocturnal haemoglobinuria.阵发性夜间血红蛋白尿的一种不寻常表现。
Br J Haematol. 2020 Feb;188(3):347. doi: 10.1111/bjh.16250. Epub 2019 Nov 21.
9
Patients with paroxysmal nocturnal hemoglobinuria demonstrate a prothrombotic clotting phenotype which is improved by complement inhibition with eculizumab.阵发性夜间血红蛋白尿患者表现出促血栓形成的凝血表型，用依库珠单抗抑制补体可改善这种表型。
Am J Hematol. 2020 Aug;95(8):944-952. doi: 10.1002/ajh.25841. Epub 2020 May 11.
10
Thrombosis and severe asthenia as priority manifestations in paroxysmal nocturnal haemoglobinuria.血栓形成和严重乏力作为阵发性夜间血红蛋白尿的首要表现。
Ann Hematol. 2012 Sep;91(9):1495-6. doi: 10.1007/s00277-012-1433-2. Epub 2012 Mar 14.
引用本文的文献
1
Atypical presentation of paroxysmal nocturnal hemoglobinuria treated by eculizumab: A case report.依库珠单抗治疗阵发性睡眠性血红蛋白尿的非典型表现：一例报告
Medicine (Baltimore). 2017 Mar;96(12):e6403. doi: 10.1097/MD.0000000000006403.
本文引用的文献
1
Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data.丹麦接受不同组合的阿司匹林、氯吡格雷和维生素 K 拮抗剂治疗的急性心肌梗死患者的出血风险：全国登记数据的回顾性分析。
Lancet. 2009 Dec 12;374(9706):1967-74. doi: 10.1016/S0140-6736(09)61751-7.
2
How I treat paroxysmal nocturnal hemoglobinuria.我如何治疗阵发性夜间血红蛋白尿症。
Blood. 2009 Jun 25;113(26):6522-7. doi: 10.1182/blood-2009-03-195966. Epub 2009 Apr 16.
3
Eculizumab for paroxysmal nocturnal haemoglobinuria.依库珠单抗用于治疗阵发性夜间血红蛋白尿症。
Lancet. 2009 Feb 28;373(9665):759-67. doi: 10.1016/S0140-6736(09)60001-5. Epub 2009 Jan 12.
4
Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria.补体抑制剂依库珠单抗治疗阵发性夜间血红蛋白尿症患者的多中心3期研究。
Blood. 2008 Feb 15;111(4):1840-7. doi: 10.1182/blood-2007-06-094136. Epub 2007 Nov 30.
5
Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria.补体抑制剂依库珠单抗对阵发性夜间血红蛋白尿患者血栓栓塞的影响。
Blood. 2007 Dec 1;110(12):4123-8. doi: 10.1182/blood-2007-06-095646. Epub 2007 Aug 16.
6
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.补体抑制剂依库珠单抗治疗阵发性夜间血红蛋白尿症。
N Engl J Med. 2006 Sep 21;355(12):1233-43. doi: 10.1056/NEJMoa061648.
7
Characteristics and prognosis of myocardial infarction in patients with normal coronary arteries.冠状动脉正常患者心肌梗死的特征与预后
Chest. 2000 Feb;117(2):333-8. doi: 10.1378/chest.117.2.333.
8
Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria.阵发性夜间血红蛋白尿中因PIG-A基因体细胞突变导致的糖基磷脂酰肌醇（GPI）锚缺陷。
Cell. 1993 May 21;73(4):703-11. doi: 10.1016/0092-8674(93)90250-t.
9
Abnormalities of PIG-A transcripts in granulocytes from patients with paroxysmal nocturnal hemoglobinuria.阵发性夜间血红蛋白尿患者粒细胞中PIG-A转录本的异常情况。
N Engl J Med. 1994 Jan 27;330(4):249-55. doi: 10.1056/NEJM199401273300404.
10
The cloning of PIG-A, a component in the early step of GPI-anchor biosynthesis.PIG-A的克隆，PIG-A是糖基磷脂酰肌醇（GPI）锚生物合成早期步骤中的一个成分。
Science. 1993 Feb 26;259(5099):1318-20. doi: 10.1126/science.7680492.
Zotero 插件